Accelerated launch of ODACTRA
ALK-Abello has announced that the FDA has completed the transfer of the tablet portfolio licences in North America (NA), and it plans to accelerate the launch of its HDM SLIT-tablet (ODACTRA) into Q4 2017 (from mid-2018). Accordingly, it has revised its full-year guidance to EBITDA of cDKK225–250m (previously cDKK300m) and free cash flow to cDKK-700m (previously cDKK-600m). We view this as a positive, and reiterate our BUY recommendation and DKK1,200 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.